Neuren Pharmaceuticals Limited (NURPF)
USD 7.63
(10.58%)
USD 7.63
(10.58%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 231.94 Million AUD | 1493.66% |
| 2022 | 14.55 Million AUD | 355.21% |
| 2021 | 3.19 Million AUD | 345.89% |
| 2020 | 717 Thousand AUD | 44.85% |
| 2019 | 495 Thousand AUD | -96.35% |
| 2018 | 13.54 Million AUD | 2046.43% |
| 2017 | 631 Thousand AUD | -79.97% |
| 2016 | 3.15 Million AUD | 88.28% |
| 2015 | 1.67 Million AUD | -42.92% |
| 2014 | 2.93 Million AUD | -38.86% |
| 2013 | 4.79 Million AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 4.64 Million AUD | -7.1% |
| 2009 | 5 Million AUD | 119.98% |
| 2008 | 2.27 Million AUD | 140.89% |
| 2007 | 944.16 Thousand AUD | 445.86% |
| 2006 | 172.96 Thousand AUD | -59.74% |
| 2005 | 429.66 Thousand AUD | -69.3% |
| 2004 | 1.39 Million AUD | -50.64% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.16 Million AUD | -92.8% |
| 2024 Q2 | 12.16 Million AUD | 0.0% |
| 2023 Q1 | 31.46 Million AUD | 116.2% |
| 2023 Q4 | 168.99 Million AUD | 99.98% |
| 2023 FY | 231.92 Million AUD | 1493.66% |
| 2023 Q3 | 84.5 Million AUD | 34.3% |
| 2023 Q2 | 62.92 Million AUD | 100.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 Q1 | - AUD | -100.0% |
| 2022 Q3 | 7.7 Million AUD | 0.0% |
| 2022 Q4 | 14.55 Million AUD | 88.79% |
| 2022 FY | 14.55 Million AUD | 355.21% |
| 2021 Q3 | 1.59 Million AUD | 0.0% |
| 2021 FY | 3.19 Million AUD | 345.89% |
| 2021 Q4 | 1.59 Million AUD | 0.0% |
| 2021 Q1 | - AUD | -100.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q4 | 358.5 Thousand AUD | 0.0% |
| 2020 Q3 | 358.5 Thousand AUD | 0.0% |
| 2020 Q1 | - AUD | -100.0% |
| 2020 FY | 717 Thousand AUD | 44.85% |
| 2019 FY | 495 Thousand AUD | -96.35% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q3 | 247.5 Thousand AUD | 0.0% |
| 2019 Q1 | - AUD | -100.0% |
| 2019 Q4 | 247.5 Thousand AUD | 0.0% |
| 2018 Q3 | 6.99 Million AUD | 0.0% |
| 2018 Q1 | - AUD | -100.0% |
| 2018 Q4 | 6.99 Million AUD | 0.0% |
| 2018 FY | 13.54 Million AUD | 2046.43% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 Q1 | - AUD | -100.0% |
| 2017 FY | 631 Thousand AUD | -79.97% |
| 2017 Q3 | 315.5 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q4 | 315.5 Thousand AUD | 0.0% |
| 2016 Q2 | 81 Thousand AUD | 0.0% |
| 2016 FY | 3.15 Million AUD | 88.28% |
| 2016 Q1 | 81 Thousand AUD | 165.57% |
| 2016 Q4 | 1.49 Million AUD | 0.0% |
| 2016 Q3 | 1.49 Million AUD | 1744.44% |
| 2015 FY | 1.67 Million AUD | -42.92% |
| 2015 Q4 | 30.5 Thousand AUD | 0.0% |
| 2015 Q1 | 806 Thousand AUD | 7.04% |
| 2015 Q2 | 806 Thousand AUD | 0.0% |
| 2015 Q3 | 30.5 Thousand AUD | -96.22% |
| 2014 Q3 | 753 Thousand AUD | 5.68% |
| 2014 Q1 | 712.5 Thousand AUD | -30.39% |
| 2014 Q4 | 753 Thousand AUD | 0.0% |
| 2014 FY | 2.93 Million AUD | -38.86% |
| 2014 Q2 | 712.5 Thousand AUD | 0.0% |
| 2013 Q3 | 1.02 Million AUD | -25.48% |
| 2013 FY | 4.79 Million AUD | 0.0% |
| 2013 Q2 | 1.37 Million AUD | 0.0% |
| 2013 Q1 | 1.37 Million AUD | 0.0% |
| 2013 Q4 | 1.02 Million AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2010 FY | 4.64 Million AUD | -7.1% |
| 2009 FY | 5 Million AUD | 119.98% |
| 2008 FY | 2.27 Million AUD | 140.89% |
| 2007 FY | 944.16 Thousand AUD | 445.86% |
| 2006 FY | 172.96 Thousand AUD | -59.74% |
| 2005 FY | 429.66 Thousand AUD | -69.3% |
| 2004 FY | 1.39 Million AUD | -50.64% |
| 2003 FY | 2.83 Million AUD | 33.68% |
| 2002 FY | 2.12 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 48.35 Million USD | -379.675% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -88.642% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -306199.192% |
| BioStem Technologies, Inc. | 16.68 Million USD | -1290.089% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -97947.853% |
| CSL Limited | 14.69 Billion USD | 98.421% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -11905.28% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -1173.147% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -35122.779% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -1370.5% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -1316181.709% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -979.905% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -352781.573% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -3829.888% |
| Marizyme, Inc. | 645.81 Thousand USD | -35814.898% |
| Genus plc | 668.8 Million USD | 65.32% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 5.452% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -234199.048% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -56448.462% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -302061.254% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -586827.476% |
| MultiCell Technologies, Inc. | 49.32 USD | -470279705.353% |
| ONE Bio Corp. | 52.29 Million USD | -343.516% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -366.487% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -474219.018% |
| Q BioMed Inc. | 284.35 Thousand USD | -81468.619% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -683.667% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -59.85% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -41488.281% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -331245.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -23217317.417% |
| Enzolytics Inc. | 52.79 Thousand USD | -439217.373% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -38015.443% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 81.086% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -165286.974% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -37468.515% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 72.372% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -23147.064% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -97947.853% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -16842.44% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -48860.8% |
| SYBLEU INC | 11.69 Thousand USD | -1982988.235% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -2877.815% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1784069.231% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -586589.938% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -6865.225% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -3380.0% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -22223.58% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -800.151% |
| CSL Limited | 14.8 Billion USD | 98.433% |
| Cellectis S.A. | 755 Thousand USD | -30620.795% |